NDA 205641 · Organon LLC
Asmanex Hfa
Mometasone Furoate · Inhalation
Last checked: Nov 19, 2026Latest source record: Aug 12, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Apr 25, 2014
Approved uses
3
Original approval plus efficacy supplements
Registered trials
251
94 Phase 3, 12 recruiting
FAERS reports
11,481
7,460 serious, 505 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 7, 2026.
ASMANEX HFA is a corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. ( 1.1 ) Important limitations: Not indicated for the relief of acute bronchospasm. ( 1.1 ) 1.1 Treatment of Asthma ASMANEX ® HFA is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Important Limitations of Use ASMANEX HFA is NOT indicated for the relief of acute bronchospasm.
Mechanism: Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of inhibitory effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation and in the asthmatic response. These anti-inflammatory actions of corticosteroids may contribute...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 12, 2019 Supplement 10 · Efficacy LabelLetter
- Jul 12, 2016 Supplement 5 · Efficacy LabelPediatric Medical ReviewLetter
- Apr 25, 2014 Original approval · Type 2 - New Active Ingredient and Type 3 - New Dosage Form ReviewSummary ReviewPediatric Medical Review
3 products under this application
- ASMANEX HFA · MOMETASONE FUROATE 0.20MG/INH · AEROSOL, METERED, INHALATION · Prescription
- ASMANEX HFA · MOMETASONE FUROATE 0.05MG/INH · AEROSOL, METERED, INHALATION · Prescription
- ASMANEX HFA · MOMETASONE FUROATE 0.10MG/INH · AEROSOL, METERED, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Mometasone Furoate" as an intervention, any sponsor and status, largest first.
- A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01471340 · 11,744 participants · Start Jan 9, 2012 · Primary completion Nov 30, 2016
Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Mometasone Furoate/Formoterol MDI 200/5 mcg and 4 more · For: Asthma
- Individualizing Treatment for Asthma in Primary Care (Full Study)Pivotal-lookingRecruiting
DARTNet InstituteGovernment (non-federal)
NCT07052942 · 3,200 participants (planned) · Start Aug 1, 2025 · Primary completion Nov 15, 2029
Drug: Inhaled corticosteroid (ICS); Azithromycin · For: Asthma; Asthma Attack; Asthma Exacerbations
Sites: Aurora, Colorado; Orlando, Florida; Kansas City, Kansas · 13 sites in all
- Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02571777 · 3,092 participants · Start Dec 8, 2015 · Primary completion Jun 14, 2019
Drug: QVM149 150/50/160; QVM149 150/50/80 and 3 more · For: Asthma
Sites: Bahía Blanca, Argentina; CABA, Argentina; Florida, Argentina · 403 sites in all
- Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00941798 · 2,283 participants · Start Jul 2009 · Primary completion May 2011
Drug: QMF149 Twisthaler®; Mometasone Twisthaler® · For: Asthma
Sites: Birmingham, Alabama; Buena Park, California; Encinitas, California · 146 sites in all
- A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02554786 · 2,216 participants · Start Dec 29, 2015 · Primary completion Nov 21, 2018
Drug: Indacaterol acetate/Mometasone furoate; Mometasone furoate and 1 more · For: Asthma
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 388 sites in all
- Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)Pivotal-lookingCompleted
ALK-Abelló A/SIndustry
NCT01700192 · 1,482 participants · Start Jan 2013 · Primary completion Apr 2015
Drug: MK-8237 tablets; Placebo tablets and 4 more · For: Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Nonseasonal
- Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + TiotropiumPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03158311 · 1,426 participants · Start Feb 5, 2018 · Primary completion Jul 12, 2019
Drug: QVM149; Salmeterol/fluticasone plus tiotropium · For: Asthma
Sites: Berazategui, Argentina; CABA, Argentina; Caba, Argentina · 163 sites in all
- A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female VolunteersPivotal-lookingCompleted
Mylan Pharmaceuticals IncIndustry
NCT02109185 · 1,307 participants · Start Sep 2013 · Primary completion Oct 2013
Drug: Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.; Nasonex® Nasal Spray, 50 μg/actuation and 2 more · For: Treatment of the Signs and Symptoms of Seasonal Allergic Rhinitis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea1,099
- drug ineffective968
- asthma945
- headache934
- cough818
- off label use797
- fatigue700
- pruritus652
- gastrooesophageal reflux disease603
- wheezing579
- nausea578
- hypersensitivity566
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 57 |
| 2005 | 56 |
| 2006 | 56 |
| 2007 | 91 |
| 2008 | 150 |
| 2009 | 122 |
| 2010 | 145 |
| 2011 | 143 |
| 2012 | 145 |
| 2013 | 96 |
| 2014 | 139 |
| 2015 | 225 |
| 2016 | 382 |
| 2017 | 424 |
| 2018 | 897 |
| 2019 | 876 |
| 2020 | 840 |
| 2021 | 1,051 |
| 2022 | 1,262 |
| 2023 | 1,238 |
| 2024 | 1,058 |
| 2025 | 1,079 |
| 2026 | 949 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Asmanex HFA (Mometasone Furoate)
2024 spending
$4.1M
Beneficiaries
11,660
29,556 claims
Per beneficiary
$351
$8.11 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $1,120,111 |
| 2022 | $7,506,929 |
| 2023 | $7,543,027 |
| 2024 | $4,089,600 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
De Corso E, Canonica GW, Heffler E, et al. · Lancet Respir Med 2025 · Clinical Trial, Phase IV, Comparative Study
- Seborrhoeic dermatitis.
Naldi L · BMJ Clin Evid 2010 · Systematic Review
- Efficacy and safety of various corticosteroids in the treatment of children with allergic rhinitis: A systematic review and network meta-analysis.
Li Y, Xiong J, Zhang Z, et al. · J Evid Based Med 2024 · Systematic Review, Network Meta-Analysis
- The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan.
Fujieda S, Matsune S, Takeno S, et al. · Laryngoscope 2021 · Clinical Trial, Phase III, Multicenter Study
- Systematic review and meta-analysis of randomized controlled trials on topical interventions for genital lichen sclerosus.
Chi CC, Kirtschig G, Baldo M, et al. · J Am Acad Dermatol 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- The add-on effect of an intranasal antihistamine with an intranasal corticosteroid in Japanese cedar pollinosis.
Haruna T, Kariya S, Higaki T, et al. · Auris Nasus Larynx 2023 · Randomized Controlled Trial
Sponsor: Organon LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.